Biotech

Zymeworks stock is a buy, Paradigm Capital says

Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) reported on Monday that Eli Lilly, one of ZYME’s pharma partners, has filed an investigational new drug (IND) submission for one of its ZYME-partnered immuno-oncology antibodies, an event which shows ...

New deal for Knight Therapeutics doesn’t move the needle, says Mackie Research

Commercial-stage specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD) has entered into a licensing agreement with Puma Biotechnology for the exclusive right to commercialize Puma’s cancer drug Nerlynx (neratinib) in Canada. The deal moves up GUD’s top an ...

The biotech sector is undervalued, John Zechner says

If you’re looking for a market sector that should do well in 2019, then biotechnology should be on your list, says John Zechner, who prefers Celgene (Celgene Stock Quote, Chart NASDAQ:CELG) over Gilead Sciences (Gilead Sciences Stock Quote, Chart NASDAQ:GILD) and likes the Nasdaq Biotechnology ET ...

Multiple Big Name Pharma Stocks Help Remedy The Pain

Pharmaceutical stocks were a standout in November. The big global names had an exceptional month. While they are categorized as defensive stocks, these heavyweights have very powerful biotechnology investments. The pharmaceutical stocks listed below all hit new highs within November. While the $SPX ...

ProMetic Life Sciences still has financial risk, Echelon Wealth Partners says

Biopharm company ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) announced its third quarter 2018 financials this week, but the focus remains on ProMetic making regulatory progress with its therapeutic protein Ryplazim (plasminogen), says analyst Douglas Loe of Echelon We ...

America’s Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub

America’s Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub By Matthew Johnson Kapoor, Anish. Cloud Gate. 2006. Chicago. – photograph by Matthew Johnson, 2018 In his latest post, Matthew Johnson takes us to Chicago – America’s “Windy City.” Known as a printing and ...

ProMetic Life Sciences has a huge upside, Paradigm Capital says

Biopharmaceutical company ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) has received the green light from the US FDA concerning the manufacturing protocol for its therapeutic protein Ryplazim (plasminogen), an event which analyst Rahul Sarugaser of Paradigm Capital call ...

Pharmaceutical Portfolio Management Reading List

This article was originally published at https://www.drugpatentwatch.com/blog/pharmaceutical-portfolio-management-reading-list/ Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries This book describes the way that pharmaceutical projects and programs are cur ...

Tetra Bio-Pharma has 56 per cent upside, Paradigm Capital says

Biopharmaceutical company Tetra Bio-Pharma (Tetra Bio-Pharma Stock Quote, Chart TSXV:TBP) has a potential turning point in its proposed clinical program to treat fibromyalgia, says analyst Rahul Sarugaser of Paradigm Capital. In a research update on Friday, Sarugaser reiterated his “Buy” rating ...

Securing the Right Space for Your Biotech Start-up

This is a guest post by Steven Lee, Senior Scientist in the Life Sciences Group at Environmental Health & Engineering (EH&E) Once you have the idea and the funding for a biotech start-up, you may think the biggest challenges are behind you. However, without proper planning and considerations, the ...